Xspray Pharma AB (publ) (XSPRAY.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 10.38 (+0.58%) as of
Key statistics
- Market cap
- 492.18M
- Forward P/E
- -6.53
- EPS (TTM)
- -3.83
- Dividend yield
- 0.00%
- 52-week range
- 9.06 – 36.15
- Beta
- -0.13
- Revenue (TTM)
- 2.47M
- Profit margin
- 0.00%
- Analyst target
- SEK 60.00
- Volume
- 18.21k
About Xspray Pharma AB (publ)
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Solna, Sweden
- Employees
- 24
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.